

Appendix Table F64. Clinical outcomes after propiverine vs. placebo, individual RCTs

Reference	Dose, mg/day	Outcome	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events/1000 treated (95% CI)
Dorschner, 2000 ²⁸²	45	Urgency symptom free	15/49	7/49	2.14 (0.96; 4.79)	0.163 (0.001; 0.325)	6 (3; 806)	163 (1; 325)
		Incontinence symptom free	24/49	15/49	1.60 (0.96; 2.66)	0.184 (-0.007; 0.374)		
		Urgency improved	29/49	19/49	1.53 (1.00; 2.33)	0.204 (0.010; 0.398)	5 (3; 97)	204 (10; 398)
		Incontinence improved	19/49	11/49	1.73 (0.92; 3.24)	0.163 (-0.016; 0.343)		
		Incontinence unchanged	6/49	23/49	0.26 (0.12; 0.58)	-0.347 (-0.514; -0.180)	-3 (-6; -2)	-347 (-514; -180)
		Urgency unchanged	5/49	23/49	0.22 (0.09; 0.53)	-0.367 (-0.531; -0.204)	-3 (-5; -2)	-367 (-531; -204)
Abrams, 2006 ²²⁷	20	Patients with ≥1 AE	30/38	12/24	1.58 (1.02; 2.43)	0.289 (0.051; 0.528)	3 (2; 20)	289 (51; 528)
	45	Patients with ≥1 AE	34/42	12/24	1.62 (1.06; 2.48)	0.310 (0.077; 0.542)	3 (2; 13)	310 (77; 542)
	20	Patients with ≥1 AE*	30/38	12/24	1.58 (1.02; 2.43)	0.289 (0.051; 0.528)	3 (2; 20)	289 (51; 528)
	45	Patients with ≥1 AE*	34/42	12/24	1.62 (1.06; 2.48)	0.310 (0.077; 0.542)	3 (2; 13)	310 (77; 542)
	45	Abnormal vision	14/42	0/24	16.86 (1.05; 270.62)	0.333 (0.182; 0.485)	3 (2; 6)	333 (182; 485)
	20	Abnormal vision	9/38	0/24	12.18 (0.74; 200.11)	0.237 (0.091; 0.382)	4 (3; 11)	237 (91; 382)
	20	Abnormal vision*	9/38	0/24	12.18 (0.74; 200.11)	0.237 (0.091; 0.382)	4 (3; 11)	237 (91; 382)
	45	Abnormal vision*	14/42	0/24	16.86 (1.05; 270.62)	0.333 (0.182; 0.485)	3 (2; 6)	333 (182; 485)
	20	Constipation	6/38	0/24	8.33 (0.49; 141.53)	0.158 (0.029; 0.287)	6 (3; 35)	158 (29; 287)
	45	Constipation	10/42	0/24	12.21 (0.75; 199.55)	0.238 (0.098; 0.378)	4 (3; 10)	238 (98; 378)
	20	Constipation*	6/38	0/24	8.33 (0.49; 141.53)	0.158 (0.029; 0.287)	6 (3; 35)	158 (29; 287)
	45	Constipation*	10/42	0/24	12.21 (0.75; 199.55)	0.238 (0.098; 0.378)	4 (3; 10)	238 (98; 378)
	20	Dry mouth	13/38	4/24	2.05 (0.76; 5.56)	0.175 (-0.037; 0.388)		
	45	Dry mouth	22/42	4/24	3.14 (1.23; 8.05)	0.357 (0.145; 0.569)	3 (2; 7)	357 (145; 569)
	20	Dry mouth*	13/38	4/24	2.05 (0.76; 5.56)	0.175 (-0.037; 0.388)		
	45	Dry mouth*	22/42	4/24	3.14 (1.23; 8.05)	0.357 (0.145; 0.569)	3 (2; 7)	357 (145; 569)
	20	Headache	1/38	0/24	1.92 (0.08; 45.37)	0.026 (-0.055; 0.108)		
	45	Headache	3/42	0/24	4.07 (0.22; 75.60)	0.071 (-0.027; 0.170)		
	20	Headache*	1/38	0/24	1.92 (0.08; 45.37)	0.026 (-0.055; 0.108)		
	45	Headache*	3/42	0/24	4.07 (0.22; 75.60)	0.071 (-0.027; 0.170)		

* at followup